Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer

28 Oct 2022

Abstract excerpt

MEK is a canonical effector of mutant KRAS; however, MEK inhibitors fail to yield satisfactory clinical outcomes in KRAS-mutant cancers. Here, we identified mitochondrial oxidative phosphorylation (OXPHOS) induction as a profound metabolic alteration to confer KRAS-mutant non-small cell lung cancer (NSCLC) resistance to the clinical MEK inhibitor trametinib. Metabolic flux analysis demonstrated that pyruvate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer
Share to Protein Tyrosine Phosphatases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36970205
DOI: 10.1016/j.apsb.2022.10.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancerPMID 36970205Read ↗

PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia.Semantic proximity Read ↗

Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.Semantic proximity Read ↗

Therapeutic strategies of metabolic reprogramming in non-small cell lung carcinoma.Semantic proximity Read ↗

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies.Semantic proximity Read ↗

Targeting <i>de novo</i> lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancerSemantic proximity Read ↗

Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterationsSemantic proximity Read ↗

Targeting metabolic reprogramming in KRAS-driven cancers.Semantic proximity Read ↗

Targeting KRAS: from metabolic regulation to cancer treatmentSemantic proximity Read ↗

SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC.Semantic proximity Read ↗

SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.Semantic proximity Read ↗

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy.Semantic proximity Read ↗

Metabolic Reprogramming Is an Initial Step in Pancreatic Carcinogenesis That Can Be Targeted to Inhibit Acinar-to-Ductal MetaplasiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.